Schizophrenia Clinical Trials in Austin, Texas
14 recruitingAustin, Texas
Showing 1–14 of 14 trials
Recruiting
Phase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
SchizophreniaMajor Depressive DisorderBipolar Disorder+2 more
Neurocrine Biosciences50 enrolled22 locationsNCT07105111
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Schizophrenia
Bristol-Myers Squibb116 enrolled8 locationsNCT07061288
Recruiting
Phase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Schizophrenia
Janssen Research & Development, LLC64 enrolled8 locationsNCT07615426
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences600 enrolled57 locationsNCT07114874
Recruiting
Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
Schizophrenia
Bristol-Myers Squibb60 enrolled13 locationsNCT07221877
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Bristol-Myers Squibb1,500 enrolled45 locationsNCT07379827
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Schizophrenia
AbbVie268 enrolled7 locationsNCT07145918
Recruiting
Phase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968
Recruiting
Phase 2
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.150 enrolled13 locationsNCT07191483
Recruiting
Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335